Hims & Hers resolves legal dispute with Novo Nordisk for weight-loss drug rights, but the shift to branded medications pressures margins and prompts a subdued revenue outlook.
The telehealth company Hims & Hers has resolved its legal dispute with pharmaceutical giant Novo Nordisk, securing official distribution rights for weight-loss medications. While this move ends a contentious chapter involving copycat drugs, it introduces significant financial pressures. Investors are now focusing on a tempered revenue outlook and contracting profit margins.
Legal Scrutiny and Mixed Analyst Sentiment
The company’s recent past continues to attract legal attention. Last Friday, the law firm Kahn Swick & Foti announced an investigation. The probe will examine whether Hims & Hers management breached its fiduciary duties to shareholders during the conflict over its previous sale of compounded GLP-1 imitation drugs.
Wall Street’s reaction to the company’s evolving situation is divided. While Leerink raised its price target to $25, other analysts point to tangible execution risks. Citigroup noted that Hims & Hers is not listed as an official retail partner on Novo Nordisk’s website. Market experts interpret this as a sign of potential ongoing friction regarding the previous sales strategy.
A Shift in Product Strategy Pressures Margins
The core of the financial challenge stems from a fundamental change in the product lineup. Hims & Hers is discontinuing the sale of its high-margin, compounded GLP-1 formulations. Its platform will now feature the more expensive branded originals, such as Wegovy. This transition is expected to materially impact profitability.
This pressure is already visible in the company’s cash flow statement. Free cash flow turned negative in the fourth quarter, dropping to -$2.6 million. Substantial investments in the company’s own pharmacy infrastructure also contributed to this decline.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Subdued Guidance and a Mounting Financial Challenge
For the closing quarter, the firm posted solid revenue growth, reaching nearly $618 million. However, its outlook for the current first quarter of 2026 is more cautious, projecting revenue between $600 million and $625 million—a range that fell short of analyst expectations. Management attributes this conservative guidance directly to the forced product shift.
The company now faces a clear arithmetic hurdle. The lower-margin profile of the official medications will require a significant increase in sales volume among its existing base of 2.5 million subscribers to meet its 2026 profitability targets. This effort unfolds within a defined financial framework, with approximately $1 billion in debt—primarily from a convertible note—on the balance sheet.
The stock recently retreated nearly nine percent as some investors locked in gains, reflecting the market’s reassessment of the company’s near-term path forward.
Ad
Hims & Hers Stock: New Analysis – 23 March
Fresh Hims & Hers information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Hims & Hers analysis…